Core Insights - E.F. Hutton & Co. served as the exclusive financial advisor to RPM Interactive, Inc. in its acquisition by Avalon GloboCare Corp., marking a significant strategic milestone for RPM [1][4] - The transaction was an all-stock merger valued at approximately $19.5 million, with Avalon acquiring RPM's Catch-Up™ Software-as-a-Service platform [2] Company Overview - E.F. Hutton & Co. is a leading investment bank providing strategic advisory and capital markets services, with a focus on innovative, high-growth companies in technology and artificial intelligence sectors [1][6] - The firm has extensive experience in executing complex mergers and acquisitions involving emerging technologies and publicly traded companies [3][6] Transaction Details - RPM merged with Avalon Quantum AI, a wholly owned subsidiary of Avalon GloboCare, acquiring a generative AI video production system designed for creating and distributing digital content [2][4] - The Catch-Up™ platform automates video production, enabling content creators and brands to publish across major digital platforms without manual editing [4] Strategic Implications - Avalon plans to utilize the Catch-Up™ platform to enhance marketing initiatives for its consumer wellness products, aiming to accelerate digital engagement and broaden audience reach [5] - The acquisition positions RPM's technology for expanded deployment, supporting long-term growth and value creation [4][5]

Core Viewpoint - Avalon GloboCare Corp. has acquired RPM Interactive, enhancing its capabilities in generative AI and addressing Nasdaq listing requirements [1][2] Group 1: Acquisition Details - The acquisition of RPM Interactive was executed as an all-stock transaction, resulting in the issuance of 19,500 shares of Series E Non-Voting Convertible Preferred Stock valued at $19.5 million [2] - Each share of Series E Preferred Stock has a stated value of $1,000 and is convertible into common stock at a price of $1.50, subject to certain conditions [2] Group 2: Technology and Product Development - RPM has developed the Catch-Up Software-as-a-Service (SaaS) platform, which automates the creation of short-form video content, including sourcing clips and generating AI commentary [3][4] - The platform is designed for content creators and media companies to produce recap-style videos efficiently, without the need for manual editing or technical expertise [4] Group 3: Strategic Integration - Avalon plans to utilize the Catch-Up platform to enhance marketing efforts for its KetoAir™ product, aiming to increase audience reach and digital engagement [5][6] - The integration of RPM's technology is expected to support Avalon's long-term value creation strategy and broaden its digital marketing capabilities [6] Group 4: Leadership and Expertise - Michael Mathews, CEO of RPM, has been appointed to Avalon's Board of Directors, bringing over two decades of experience in technology and digital media [6][9] - His background includes leadership roles in performance marketing and AI-enabled content systems, which are expected to contribute to Avalon's growth strategy [9] Group 5: Future Plans - Marketing for the Catch-Up platform is set to commence immediately after the new year, indicating a proactive approach to market entry [3] - Avalon is also pursuing a merger with YOOV Group Holdings Limited, which will further enhance its capabilities in AI automation solutions [10]

Core Viewpoint - Avalon GloboCare Corp. has acquired RPM Interactive, Inc. to enhance its digital marketing capabilities and strengthen its balance sheet through an all-stock transaction valued at $19.5 million [1][2]. Transaction Structure - RPM merged into Avalon Quantum AI, LLC, a newly formed wholly owned subsidiary, with Avalon issuing 19,500 Series E non-voting convertible preferred shares [2]. - The preferred shares can be converted into common stock at $1.50 per share after May 12, 2026, pending shareholder approval [2]. Technology and Product Integration - RPM's "Catch-Up" SaaS platform automates the creation and distribution of short-form videos, allowing Avalon to produce branded content efficiently [3]. - The platform sources clips, generates AI narration and avatars, and publishes content across major platforms, with commercialization expected early next year [3]. Strategic Rationale - Avalon intends to utilize the AI platform to support marketing efforts for KetoAir, an FDA-registered breathalyzer aimed at helping consumers track wellness and metabolic health [4]. Leadership and Governance - RPM's CEO, Michael Mathews, has been appointed to Avalon's board of directors as part of the acquisition deal [6]. - Avalon is also pursuing a separate merger with YOOV Group Holdings Limited, with an S-4 registration statement filed with the SEC [6]. Market Reaction - Following the announcement, ALBT shares were trading 13.97% lower at $1.17 in premarket trading [6].

Core Insights - Avalon GloboCare Corp. announced significant advancements for its KetoAir™ product in Q3 2025, including expanded deployment, a first-responder metabolic health program, and entry into international markets [1][3] Product Development - KetoAir™ is a handheld breathalyzer designed for ketogenic health management, measuring breath acetone concentration (BrAce), which indicates fat metabolism and ketosis [3] - The device is FDA-registered as a Class I medical device and is compatible with both Apple and Android devices, available for purchase through the Apple App Store and Google Play Store [3][5] Market Expansion - Avalon launched the KetoAir™ in the United Kingdom on September 1, 2025, marking its first international expansion [7] - The company showcased KetoAir™ at the London Health Optimization Summit on September 13-14, 2025, highlighting its integration into wellness and metabolic health programs [7] Health Initiatives - In August 2025, Avalon, in collaboration with Saga Health and SpecialtyHealth, launched the "Nevada POOL/PACT Holistic Health Reset" program for 50 first responders, utilizing KetoAir™ for daily monitoring of metabolic changes [7] - Mid-program results from the Nevada initiative indicated individual improvements in metabolic health, potentially driven by better diet, exercise, and sleep quality [7]

Revenue and Income - For the three months ended September 30, 2025, real property rental revenue was $350,099, an increase of $4,940 or 1.4% compared to $345,159 for the same period in 2024[264]. - For the nine months ended September 30, 2025, real property rental revenue was $1,050,305, an increase of $62,671 or 6.3% compared to $987,634 for the same period in 2024[264]. - Real property operating income for the three months ended September 30, 2025 was $115,733, an increase of $16,102 or 16.2% compared to $99,631 for the same period in 2024[268]. - Real property operating income for the nine months ended September 30, 2025 was $284,472, an increase of $90,980 or 47.0% compared to $193,492 for the same period in 2024[268]. - For the nine months ended September 30, 2025, the company reported income from Lab Services MSO of $392,677, which included its share of net income and amortization of identifiable intangible assets[270]. Expenses and Losses - The company incurred a working capital deficit of approximately $11,515,000 at September 30, 2025, with recurring net losses of approximately $16,195,000 for the nine months ended September 30, 2025[253]. - The company generated negative cash flow from operating activities of approximately $4,389,000 for the nine months ended September 30, 2025[253]. - For the three months ended September 30, 2025, advertising and marketing expenses increased by $104,287, or 72.1%, compared to the same period in 2024, while for the nine months, the increase was $390,329, or 154.7%[273]. - Professional fees for the three months ended September 30, 2025, rose by $945,150, or 311.6%, primarily due to increased consulting and legal service fees related to a potential merger with YOOV Group[275]. - Compensation and related benefits decreased by $112,976, or 32.9%, for the three months ended September 30, 2025, and by $159,333, or 15.1%, for the nine months, mainly due to reduced compensation for the executive officer[275]. - Miscellaneous taxes increased by $31,600, or 263.3%, for the three months ended September 30, 2025, primarily due to an increase in Delaware state franchise tax[275]. - Loss from operations for the three months ended September 30, 2025, was $76,193, a decrease of $1,193,768, or 94.0%, compared to the same period in 2024[277]. - Net loss for the three months ended September 30, 2025, was $254,268, a decrease of $1,424,932, or 84.9%, compared to the same period in 2024[282]. - The net loss attributable to common shareholders for the nine months ended September 30, 2025, was $16,032,504, or $6.10 per share, representing an increase of $10,853,765, or 209.6%[284]. - Comprehensive loss for the three months ended September 30, 2025, was $253,997, compared to $1,676,157 for the same period in 2024[286]. Cash Flow and Capital - As of September 30, 2025, the company's cash balance was approximately $334,000, a decrease from $2,856,000 on December 31, 2024[288]. - The working capital deficit increased by $868,585 to $11,514,642 at September 30, 2025, compared to $10,646,057 at December 31, 2024, primarily due to a decrease in cash and increases in accrued liabilities[290]. - Net cash used in operating activities for the nine months ended September 30, 2025, was $4,388,557, reflecting a consolidated net loss of approximately $16,195,000[292]. - Net cash flow provided by investing activities was $752,635 for the nine months ended September 30, 2025, compared to a net cash flow used of $100,000 for the same period in 2024[295]. - Net cash flow provided by financing activities was $1,112,871 for the nine months ended September 30, 2025, down from $4,726,942 in the same period of 2024[296]. - The company expects cash used in operating activities to increase in the next 12 months due to new product development and increased marketing efforts[294]. - The company estimates that its available cash will be insufficient to meet its cash requirements under current operating expectations, necessitating significant additional capital[298]. Operational Changes and Future Outlook - The company suspended all research and development efforts related to cellular therapy to focus on product commercialization[251]. - The KetoAir breathalyzer device is registered with the U.S. FDA as a Class I medical device and is marketed for the diabetes and obesity markets[244][247]. - The company sold its 40% equity interest in Lab Services MSO on February 26, 2025, resulting in no income from this investment for the three months ended September 30, 2025[269]. - The company faces substantial doubt about its ability to continue as a going concern, dependent on raising additional capital and generating sufficient revenues[287]. - The unrealized foreign currency translation gain for the nine months ended September 30, 2025, was approximately $700, compared to $2,800 for the same period in 2024[299]. - The company has ceased all operations in China since 2022, limiting exposure to foreign currency exchange rate fluctuations[299]. - The increase in working capital requirements is attributed to financing current business operations and capital for acquisitions[301].

Core Viewpoint - Avalon GloboCare Corp. is launching the KetoAir™ breathalyzer device in the UK, expanding its market presence following its U.S. launch, targeting individuals on ketogenic diets for health management [1][3]. Product Overview - KetoAir™ is a handheld breathalyzer that measures breath acetone concentration (BrAce), indicating fat metabolism and ketosis, and is registered as a Class I medical device with the U.S. FDA [2][4]. - The device is designed for users pursuing ketogenic diets for weight loss, athletic performance, or therapeutic purposes, utilizing advanced nano-sensor technology for real-time metabolic insights [2][3]. Market Strategy - The launch in the UK is seen as a strategic move to capitalize on the growing adoption of ketogenic and low-carb diets, positioning KetoAir™ as a tool to help individuals achieve their health and wellness goals [3]. - The product will be available for purchase starting September 1, 2025, through the dedicated website [1][3]. Company Background - Avalon GloboCare Corp. focuses on developing precision diagnostic consumer products and advancing intellectual property in cellular therapy, with plans to explore additional diagnostic uses for the breathalyzer technology [4].

Revenue and Income - Real property rental revenue for Q2 2025 was $350,406, an increase of $22,519 or 6.9% compared to Q2 2024[263] - Real property operating income for Q2 2025 was $99,329, an increase of $56,930 or 134.3% compared to Q2 2024[267] - For the six months ended June 30, 2025, real property rental revenue was $700,206, up $57,731 or 9.0% from the same period in 2024[263] Expenses and Losses - Real property operating expenses for Q2 2025 decreased to $251,077, down $34,411 or 12.1% from Q2 2024[265] - Loss from operations for the three months ended June 30, 2025, amounted to $3,887,987, representing an increase of $2,383,624, or 158.4%, compared to the same period in 2024[274] - Other expense, net, totaled $9,570,611 for the three months ended June 30, 2025, representing an increase of $8,942,948, or 1,424.8%, primarily due to increased third-party interest expense and loss on extinguishment of debt[276] - Net loss for the three months ended June 30, 2025, was $13,458,598, an increase of $11,326,572, or 531.3%, compared to the same period in 2024[279] - The net loss attributable to common shareholders for the three months ended June 30, 2025, was $13,458,598, or $6.22 per share, compared to $2,132,026, or $2.85 per share, for the same period in 2024[280] - Comprehensive loss for the three months ended June 30, 2025, was $13,458,494, compared to $2,129,320 for the same period in 2024[283] Cash Flow and Working Capital - The company incurred a working capital deficit of approximately $14,132,000 as of June 30, 2025[252] - The company generated negative cash flow from operating activities of approximately $3,028,000 for the six months ended June 30, 2025[252] - As of June 30, 2025, the company's cash balance was approximately $201,532, a decrease of 92.9% from $2,856,309 on December 31, 2024[286] - The working capital deficit increased by $3,486,262 to $14,132,319 at June 30, 2025, primarily due to a decrease in cash and increases in accrued liabilities[286] - Net cash used in operating activities for the six months ended June 30, 2025 was $3,027,822, reflecting a consolidated net loss of approximately $15,941,000[289] - The company reported a net cash flow provided by financing activities of $277,636 for the six months ended June 30, 2025, a significant decrease from $2,010,577 in the same period of 2024[292] - The company expects cash used in operating activities to increase in the next 12 months due to rising operational costs and working capital requirements[291] Assets and Liabilities - The total current assets decreased by 71.2% from $3,236,498 on December 31, 2024 to $933,088 on June 30, 2025[286] - The total current liabilities increased by 8.5% from $13,882,555 on December 31, 2024 to $15,065,407 on June 30, 2025[286] Business Operations and Strategy - The company has suspended all research and development efforts related to cellular therapy to focus on product commercialization[250] - The company plans to target the diabetes and obesity markets with the KetoAir breathalyzer device[246] - The KetoAir device is registered as a Class I medical device with the U.S. FDA and is paired with an "AI Nutritionist" software program[248] - The company has ceased all operations in China since 2022, limiting future revenue generation from that market[296] - The company will need to raise significant additional capital to fund operations and provide working capital, with no assurance that financing will be available on acceptable terms[295] Financial Viability - The company has a limited operating history and its continued growth is dependent on generating rental revenue and obtaining additional financing, raising substantial doubt about its ability to continue as a going concern[285]

Core Viewpoint - Avalon GloboCare Corp. has announced a wholesale distribution agreement with Saga Health Corporation for the KetoAir™ breathalyzer device, aimed at first responders as part of Saga's Holistic Health Reset Program [1][3]. Company Overview - Avalon GloboCare Corp. (NASDAQ: ALBT) specializes in precision diagnostic consumer products and cellular therapy intellectual property [5]. - The company is currently marketing the KetoAir™ breathalyzer, which is registered as a Class I medical device with the U.S. FDA [5]. - Avalon also focuses on advancing its intellectual property portfolio through existing patent applications and operates commercial real estate [5]. Product Details - The KetoAir™ breathalyzer is designed for ketogenic health management, measuring breath acetone concentration (BrAce) to indicate fat metabolism and ketosis [2]. - It is intended for users on ketogenic diets for weight loss, athletic performance, or therapeutic purposes, utilizing nano-sensor technology for real-time insights [2]. - The device is compatible with both Apple and Android devices and is available on the Apple App Store and Google Play Store [2]. Partnership Significance - The agreement with Saga Health is seen as a milestone for accelerating the commercial expansion of the KetoAir™ device [3]. - The collaboration aims to meet the growing demand for personalized, real-time monitoring of BrAce among those pursuing ketogenic lifestyles [3]. - Saga Health's Holistic Health Reset Program provides personalized nutritional guidance and tools like the KetoAir™ breathalyzer to improve participants' health [6].

Core Points - Avalon GloboCare Corp. announced the issuance of a new standard patent for its CAR-T and CAR-Natural Killer (NK) cell technology in Hong Kong, marking a significant milestone in its global intellectual property strategy [1][2][3] - The patent, effective from February 21, 2020, provides 20 years of protection for the company's proprietary technology, reinforcing its competitive position in the field of cell-based immunotherapy [2][3] - The patented technology aims to enhance the manufacturing, expansion, survival, and therapeutic efficacy of CAR-T and CAR-NK cells, which is crucial for advancing treatment options in hematologic malignancies [3][7] Company Overview - Avalon GloboCare Corp. is focused on developing precision diagnostic consumer products and advancing intellectual property in cellular therapy, including the marketing of the KetoAir™ breathalyzer device [4] - The company is also engaged in the development of additional diagnostic uses for its breathalyzer technology, which is registered as a Class I medical device with the U.S. FDA [4] - Avalon continues to expand its intellectual property portfolio through existing patent applications and also owns and operates commercial real estate [4]

Core Viewpoint - Avalon GloboCare Corp. has entered into a definitive agreement with Qi Diagnostics to co-develop a VOC nanosensor-based point-of-care cannabis breathalyzer aimed at enhancing public safety and supporting real-time detection of cannabis-impaired driving [1][2][3] Company Overview - Avalon GloboCare Corp. (NASDAQ: ALBT) specializes in precision diagnostic consumer products and is advancing intellectual property in cellular therapy [4] - The company is currently marketing the KetoAir™ breathalyzer device, which is registered with the U.S. Food and Drug Administration as a Class I medical device [4] Strategic Collaboration - The collaboration involves Avalon, its subsidiary Q&A Distribution, LLC, and Qi Diagnostics to jointly design, validate, and develop a prototype for the cannabis breathalyzer device [2] - This partnership aims to combine Avalon's regulatory expertise with Qi Diagnostics' VOC nanosensor technology to create a non-invasive cannabis detection solution [3] Public Health Impact - The cannabis breathalyzer is intended to support law enforcement and workplace safety by providing a real-time detection solution for cannabis impairment [3]